Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthri…

To ascertain if etoricoxib increases the risk of gastrointestinal adverse events (GAEs) compared with placebo, diclofenac, and naproxen in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA).

Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-…

To assess the comparative efficacy of traditional non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclo-oxygenase-2 inhibitors in patients with acute gout.

Nationwide Etoricoxib Injection Clinical Experience (NICE): Real-World Eviden…

Pain is a major health issue globally. Etoricoxib, a highly selective COX-2 inhibitor, given orally, has been found to be efficacious and safe in the management of acute and chronic pain. Oral etoricoxib has been extensively studied; however, there is a lack of research exploring the use of etoricoxib via alternative routes, specifically intramuscular (IM) injection. This study aimed to evaluat…

Comparing pre‑ and postoperative etoricoxib administration versus only p…

This study aimed to compare the impact of pre- and postoperative etoricoxib administration versus only postoperative on third molar extraction sequelae and oral health quality of life

Etoricoxib Coated Tablets: Bioequivalence Assessment between Two Formulations…

Etoricoxib is a non-steroidal anti-inflammatory drug with high selectivity for cyclooxygenase 2 (COX-2), exerting a pronounced anti-inflammatory effect with fewer adverse events when compared to COX-1 inhibitors. The present study aimed to evaluate the bioequivalence between two etoricoxib-coated tablet formulations to meet regulatory requirements for a branded generic product registration in B…

Comparison of Cefdinir and Cefaclor in Treatment of Community-Acquired Pneumonia

Six hundred ninety patients were enrolled in a multicenter, randomized, double-blind trial comparing the efficacy and safety of cefdinir with those of cefaclor in the treatment of community-acquired pneumonia. Patients received either 10 days of treatment with cefdinir (n 5 347) at 300 mg twice daily or 10 days of treatment with cefaclor (n 5 343) at 500 mg three times daily. Microbiological…

Cefdinir Versus Cephalexin for the Treatment of Skin and Skin-Structure Infec…

Because of increasing resistance to older antimicrobial agents, newer drugs need to be evaluated for the treatment of skin and skin-structure infections (SSSIs). This double-masked, randomized, comparative, multicenter study enrolled patients aged 13 years or older with SSSIs to receive either cefdinir 300 mg BID or cephalexin 500 mg QID for 10 days

Cefdinir: an oral cephalosporin for the treatment of respiratory tract infect…

Cefdinir is an oral third-generation cephalosporin (also known as an advanced-spectrum or generation cephem) with good in vitro activity against the pathogens responsible for community-acquired respiratory tract infections and uncomplicated skin and skin structure infections. The drug distributes very well in respiratory tract tissues and fluids, as well as skin blisters and ear fluids; its pha…

Comparison of a 5 day regimen of cefidinir with a 10day regimen of cefpozil f…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Cefdinir: A Review of its Use in the Management of Mild-to-Moderate Bacterial…

Cefdinir (Omnicef) is an oral third-generation cephalosporin with good in vitro activity against many pathogens commonly causative in community-acquired infections. The drug provides good coverage against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae, the most common respiratory tract pathogens. Cefdinir is stable to hydrolysis by commonly…